MING YU PHARMA Re-Files HKEX Listing Application; Morgan Stanley, BofA Securities and CITIC Securities Appointed Joint Sponsors
NewTimeSpace News: Ming Yu Pharmaceutical Limited re-submitted its listing application to HKEX on 8 July, with Morgan Stanley, BofA Securities and CITIC Securities acting as joint sponsors. Founded in 2018, it is an oncology-focused biotech company centred on integrative oncology, specialising in antibody-drug conjugates and advanced immunotherapies. Its pipeline comprises 11 independently discovered and developed candidates including two core assets.
NewTimeSpace News: Ming Yu Pharmaceutical Limited re-filed a listing application with The Stock Exchange of Hong Kong Limited on 8 July 2026. Morgan Stanley, BofA Securities and CITIC Securities have been appointed as the joint sponsors.
Founded in 2018, the Company is a biotechnology enterprise focusing on integrative oncology, dedicated to the research and development combining antibody-drug conjugates (ADCs) and advanced immunotherapies. As of the latest practicable date, its product pipeline covers 11 candidate products, all independently discovered and developed.
Its core asset MHB036C is an ADC candidate for solid tumours, mainly indicated for first-line and subsequent-line treatment of non-small cell lung cancer and breast cancer. MHB018A is an antibody candidate developed for thyroid eye disease, with active thyroid eye disease as its primary indication.
The Company has built a robust clinical-stage oncology portfolio based on its proprietary ADC platform and PD-1/VEGF bispecific antibodies, together with late-stage autoimmune assets advancing towards commercialisation.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- CSOP NASDAQ-100 Index Daily (2x) Leveraged Product(07266.HK) Rises 1.35% Intraday at HK$40.68
- CSOP Huatai-PB CSI 300 ETF(03133.HK) Rises 1.76% Intraday, NAV Per Unit Stands at HK$11.917
- Hwabao WP CSI Electronic 50 ETF (515260) rises 5.90%, with a share increase of 16.00 million units over the past 2 weeks
- E Fund CSI Chip Industry ETF(516350) rises 6.59%, with a scale increase of 124 million yuan over the past 2 weeks
- Global X China Robotics And Ai Etf(02807.HK) Rises 1.05% in Afternoon Trade, Turnover at HKD 6.4862 Million
